针对宿主的先天和适应性免疫，以实现慢性乙型肝炎的功能

StephenW

Vaccines (Basel). 2020 May 11;8(2). pii: E216. doi: 10.3390/vaccines8020216.
Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B.
Ezzikouri S1,2, Kayesh MEH2,3, Benjelloun S1, Kohara M4, Tsukiyama-Kohara K2.
Author information

1
    Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, Casablanca 20250, Morocco.
2
    Transboundary Animal Diseases Centre, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima 890-0065, Japan.
3
    Department of Microbiology and Public Health, Faculty of Animal Science and Veterinary Medicine, Patuakhali Science and Technology University, Barishal 8210, Bangladesh.
4
    Department of Microbiology and Cell Biology, The Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.

Abstract

Despite the availability of an effective preventive vaccine for hepatitis B virus (HBV) for over 38 years, chronic HBV (CHB) infection remains a global health burden with around 257 million patients. The ideal treatment goal for CHB infection would be to achieve complete cure; however, current therapies such as peg-interferon and nucleos(t)ide analogs are unable to achieve the functional cure, the newly set target for HBV chronic infection. Considering the fact functional cure has been accepted as an endpoint in the treatment of chronic hepatitis B by scientific committee, the development of alternative therapeutic strategies is urgently needed to functionally cure CHB infection. A promising target for future therapeutic strategies is immune modulation to restore dysfunctional HBV-specific immunity. In this review, we provide an overview of the progress in alternative therapeutic strategies, including immune-based therapeutic approaches that enhance host innate and adaptive immunity to achieve and increase the functional cure from CHB infection.
KEYWORDS:

HBV; adaptive immunity; host factors; innate immunity; therapeutic vaccine

PMID:
    32403281
DOI:
    10.3390/vaccines8020216

StephenW

疫苗（巴塞尔）。 2020年5月11日； 8（2）。 pii：E216。 doi：10.3390 / vaccines8020216。
针对宿主的先天和适应性免疫，以实现慢性乙型肝炎的功能治愈。
Ezzikouri S1,2，Kayesh MEH2,3，Benjelloun S1，Kohara M4，Tsukiyama-Kohara K2。
作者信息

1个
    摩洛哥卡斯特布兰卡巴斯德巴斯德研究所病毒肝炎实验室病毒学科，摩洛哥，卡萨布兰卡20250。
2
    鹿儿岛大学动物医学联合学院跨界动物疾病中心，日本鹿儿岛890-0065。
3
    Patuakhali科技大学动物科学与兽医学院微生物学与公共卫生系，孟加拉国Barishal 8210。
4
    东京都医学科学研究所微生物与细胞生物学系，日本东京156-8506。

抽象

尽管可以使用有效的预防性乙型肝炎病毒疫苗已有38年以上，但慢性HBV（CHB）感染仍然是全球健康负担，约有2.57亿患者。 CHB感染的理想治疗目标是完全治愈。然而，目前的治疗方法例如聚乙二醇干扰素和核苷酸（t）化物类似物无法实现功能性治疗，这是HBV慢性感染的新目标。考虑到功能性治疗已被科学委员会接受为慢性乙型肝炎治疗的终点这一事实，迫切需要开发其他治疗策略来功能性治疗CHB感染。未来治疗策略的有希望的目标是免疫调节，以恢复功能异常的HBV特异性免疫。在本文中，我们概述了其他治疗策略的进展，包括基于免疫的治疗方法，这些方法可增强宿主固有免疫力和适应性免疫力，以实现并增加CHB感染的功能性治愈。
关键字：

乙肝病毒适应性免疫宿主因素；先天免疫;治疗性疫苗

PMID：
    32403281
DOI：
    10.3390 /疫苗8020216